You are here
FDA Says Oncophage Clinical Trials Can Resume
"Our team worked hard to provide the information within our targeted timelines," said Garo H. Armen, PhD, chairman and CEO of Antigenics. "We are grateful for the FDA's rapid and thorough review of our submission."
The FDA had placed two Antigenics studies on partial clinical hold to review product characterization data. All other Oncophage trials, including Phase I and II studies, were unaffected by the hold.
Source: Antigenics Inc.